Pfizer at Lehman Brothers Global Health Care Conference
Upcoming SlideShare
Loading in...5
×
 

Pfizer at Lehman Brothers Global Health Care Conference

on

  • 2,250 views

 

Statistics

Views

Total Views
2,250
Views on SlideShare
2,245
Embed Views
5

Actions

Likes
0
Downloads
19
Comments
0

1 Embed 5

http://www.slideshare.net 5

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Pfizer at Lehman Brothers Global Health Care Conference Pfizer at Lehman Brothers Global Health Care Conference Presentation Transcript

  • Lehman Brothers Global Healthcare Conference Martin Mackay President, Global Research & Development March 19, 2008
  • Cautionary Language The discussions at this meeting will include forward- looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in our 2007 Annual Report on Form 10-K and in our reports on Form 10-Q and 8-K. These reports are available on our website at www.pfizer.com in the “Investors – SEC Filings” section.
  • R&D Five Point Plan Aggressively Deliver the Phase 2 and Phase 3 Portfolio Prioritize Our Portfolio to Deliver the Most Value Become a Top-Tier Biotherapeutics Company Dramatically Raise the Bar on Productivity Pursue the Best External Science
  • Rich In Substrate 85 distinct new molecular entities in our pipeline 26 biological programs in preclinical/clinical development Pipeline breadth and depth in 10 therapeutic areas Aggressive goal to rebuild our Phase 3 portfolio Total of 15 - 20 Phase 3 starts 2008 - 2009 Phase 3 total programs grow to 24 - 28 by December 2009 15 - 20 regulatory submissions between 2010 - 2012
  • Pfizer R&D Pipeline (as of February 28, 2008) Over 300 Discovery Projects Phase 1 Phase 2 Approved Phase 3 47 37 In Reg. Selzentry 16 Lyrica 2 Fibromyalgia fesoterodine (EU) Accelerating Pipeline with Sharpened Focus on Key Disease Areas Strong flow of medicines expected to progress from Phase 2 to Phase 3
  • Today’s Phase 3 Portfolio axitinib – Pancreatic Cancer PD-332334 – GAD tremelimumab – Melanoma S,S-reboxetine – Fibromyalgia NMEs apixaban – VTE Prevention Zithromax/chloroquine – Malaria CP-945598 – Obesity New Indications apixaban – / Atrial Fibrillation
  • Potential New Indications Expected To Drive Value Colorectal es nu ve Non Small Cell Lung Re Hepatocellular Carcinoma Breast Renal Cell Carcinoma & Gastrointestinal Stromal Tumor Time
  • axitinib: Potential New Phase 3 Indications Study 1016 ECOG PS 0/1 Ongoing Phase 3 trial in 1.0 axitinib+gemcitabine pancreatic cancer (n=63) Median: 7.2 mo Anticipate at ASCO (95% CI: 6.0, 12.5) 0.8 Overall Survival Probability gemcitabine (n=31) Additional information on both Median: 5.7 mo pancreas and renal cell trials (95% CI: 4.1, 8.8) 0.6 Expect two new Phase 3 starts: 0.4 Renal cell cancer Non-small cell lung cancer 0.2 Hazard ratio = 0.683 (95% CI: 0.42, 1.11) 0 0 2 4 6 8 10 12 14 16 18 20 Time (months) Spano J et al., ECCO 2007
  • Projected 15–20 Phase 3 Starts 2008–2009 PF-3187207 PF-885706 – GERD PF-868554 PF-734200 – Glaucoma – HCV – Diabetes PF-299804 – Cancer CP-751871 PF-4194471 PF-4522625 PH-797804 – RA – Lung Cancer – HIV – Seasonal Flu NMEs IV sulopenem/Oral PF-4383119 CP-690550 UK-453061 sulopenem pro-drug – OA Pain – RA – HIV – Bacterial Infections PD-200390 – Insomnia apixaban – VTE PF-4383119 treatment & ACS – Chronic Pain axitinib – RCC & tremelimumab – CRC New Lung S,S-reboxetine – DPN Indications
  • CP-751871 (IGF-1R Ab): Proof Of Concept Established In 1st Line NSCLC Carboplatin/Paclitaxel (SOC) Study Treatment-naïve Stage IIIB/IV NSCLC patients Design Carboplatin/Paclitaxel + CP-751 60 Response Rate (%) 50 Highly specific fully 40 human antibody 30 Well tolerated – high potential to combine 20 10 Broad proof-of-concept development plan 0 underway SOC SOC+CP-751871 (n=48) (n=25) All Adeno Nonadeno Phase 2 Tumor Shrinkage Needs to Translate to Phase 3 Survival Benefit for Registration * carboplatin/paclitaxel Karp et al ASCO 2007; Karp et al IASLC 2007
  • CP-690550: JAK-3 Inhibitor RA Phase 2a Response Rate 100 80 60 40 20 0 0 2 4 6 Weeks Phase 2b dose ranging in rheumatoid Placebo 5 mg 15 mg 30 mg arthritis ongoing – anticipate Kremer JM et al, ACR 2006 presentation at ACR 2008 Simultaneous Development Programs in Psoriasis, Asthma, Transplant Rejection, Rheumatoid Arthritis and Crohn’s Disease
  • PF-4383119 (RN-624): Nerve Growth Factor Inhibitor Heavy Projected 1st Biotherapeutic for Pain Chain Blocks Nerve Growth Factor (NGF) Humanized monoclonal antibody NGF Efficacy demonstrated in Phase 2 osteoarthritis (OA) pain study Favorable safety profile to date >600 patients treated Light Chain
  • PF-4383119: Osteoarthritis Knee Pain Single IV Infusion: Mean Change from Baseline (mm) Over 8 Weeks Panel 1 Panel 2 Baseline Pain = 43–46 mm Baseline Pain = 54–60 mm n=12 n=6 n=6 n=6 n=26 n=27 n=26 0 -5 -10 -15 -20 -25 * * -30 * * -35 Placebo 0.1 mg/kg 0.3 mg/kg 1.0 mg/kg Encouraging Phase 1/2 Efficacy and Safety Data * p<0.05 vs placebo
  • Projected 15–20 Submissions 2010–2012 axitinib – Pancreatic Cancer Zithromax/chloroquine PF-734200 – Diabetes – Malaria S,S-reboxetine PD-200390 – Insomnia – Fibromyalgia PF-299804 – Cancer CP-751871 CP-945598 – Obesity PF-885706 – GERD – 3rd Line NSCLC NMEs PD-332334 – GAD PF-4522625 – Seasonal Flu PF-4383119 – OA Pain IV sulopenem / Oral PH-797804 – RA CP-690550 – RA sulopenem pro-drug PF-868554 – HCV – Bacterial Infections PF-4194471 – HIV UK-453061 – HIV axitinib – 1st Line S,S-reboxetine – DPN nd NSCLC & 2 Line RCC CP-690550 – Psoriasis apixaban – VTE PF-4383119 New Treatment, AF & Acute – Chronic Pain Coronary Syndrome Indications /
  • 86 Biotherapeutics In The Pipeline Research Development Marketed 60 26 5 $1.4 B 2007 Diverse Portfolio Revenues 8 TAs (dalteparin sodium injection) (interferon beta-1a) 6 Modalities 53 MAbs 8 Vaccines (pegvisomant for injection)
  • Delivery In Action Selzentry/Celsentri Approved for Treatment Experienced HIV (US/EU) Approved for Smoking Cessation, PAH (Japan) Champix, Revatio Zithromax SR Submitted for Bacterial Infections (Japan) Submitted for Osteoporosis Fablyn Spiriva Respimat Submitted for COPD Xalacom Submitted for Glaucoma (Japan) PD-332334, S,S-reboxetine, Eraxis/Vfend, Geodon Advanced to Phase 3 Adj Depression, axitinib & Neurontin Peds (Japan) Potential New Oncology Sutent, axitinib and tremelimumab Indications Business Development Encysive, CovX, Serenex, Coley 3 POCs, 11 FIPs, 17 FIHs Early Portfolio
  • Strong And Growing Portfolio New In-Line Established (glipizide) Extended Release Tablets Dynastat ® IV/IM (parecoxib sidico injectable)